Emergent BioSolutions (NYSE:EBS) Raised to Buy at StockNews.com

Emergent BioSolutions (NYSE:EBS) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday.

Several other equities research analysts have also weighed in on the stock. Rodman & Renshaw reiterated a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a report on Friday, September 13th. Benchmark increased their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, November 7th.

Emergent BioSolutions Price Performance

Shares of EBS stock opened at $9.97 on Tuesday. Emergent BioSolutions has a 52-week low of $1.42 and a 52-week high of $15.10. The stock has a market cap of $540.17 million, a PE ratio of -2.43 and a beta of 1.57. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm’s 50 day moving average price is $8.63 and its two-hundred day moving average price is $7.96.

Institutional Investors Weigh In On Emergent BioSolutions

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. American Century Companies Inc. increased its stake in Emergent BioSolutions by 240.9% in the 2nd quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after buying an additional 623,201 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Emergent BioSolutions by 14.7% in the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after acquiring an additional 436,911 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Emergent BioSolutions by 74.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock valued at $6,192,000 after acquiring an additional 316,700 shares during the period. Federated Hermes Inc. grew its position in shares of Emergent BioSolutions by 1,314.0% in the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after acquiring an additional 253,960 shares during the period. Finally, Marshall Wace LLP grew its position in shares of Emergent BioSolutions by 75.4% in the 2nd quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock valued at $3,702,000 after acquiring an additional 233,341 shares during the period. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.